19.12.2016 • News

Dow to Convert Preferred Shares

(c) Dow
(c) Dow

Dow Chemical has announced it will convert $4 billion worth of preferred shares held by Warren Buffett's Berkshire Hathaway investment vehicle and Kuwait's sovereign wealth fund into common equity.

Buffett, the billionaire US investor, purchased 3 million of Dow’s preferred shares for $3 billion in April 2009 to help the chemical giant finance its acquisition of chemical producer Rohm & Haas. Kuwait Investment Authority (KIA) bought 1 million of the company’s preferred shares for $1 billion.

Converting the shares with an annual dividend rate of 8.5% was made contingent on the Dow stock trading above $53.72 per share for any 20 trading days in a 30-day window. The share price recorded gains of nearly 10% in the past month.  After the conversion, Buffett will hold about 6% of the chemical company KIA around 2 percent.

According to the news agency Reuters, Dow has paid Buffett $255 million in dividends every year since the purchase, netting the investor gains about $1.8 billion since 2009. Kuwait Investment Authority netted nearly $600 million in the same period.

Following the conversion of the preferred shares, Dow will issue 96.8 million new common shares, representing nearly 9% of its 1.12 billion shares outstanding on Sept. 30.

Interview

Driving Sustainability Through Collaboration
Building Green Practices Across the Chemical Supply Chain

Driving Sustainability Through Collaboration

Together for Sustainability (TfS) is a pioneering, member-led initiative working to accelerate sustainable and resilient chemical supply chains. TfS President Jennifer Jewson discusses the origins of TfS, its evolving goals, its present-day challenges, and the initiative’s enduring impact and outlook for the future.

Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read